QuantumBio Intelligence Surges Over 6% in Early Trading as PandaClaw Officially Launches as Comprehensive Bioanalysis AI Agent

SadMoneyMeow · 2026-03-24T09:08:45+00:00

XtalPi's stock price rose more than 5%, recently launching a new feature called PandaClaw, which combines AI with bioinformatics to facilitate target discovery and disease research. This feature represents an important milestone in its "pharmaceutical super intelligence" initiative.

SadMoneyMeow

2026-03-24 09:08:45

Abstract generation in progress

Silicon Smart (03696) surged over 6% intraday. As of the time of writing, the stock price increased by 5.40% to HKD 51.90, with a trading volume of HKD 34.9616 million.

On March 23, according to Silicon Smart’s official Weibo, the company recently announced the launch of PandaClaw, a revolutionary new feature within its proprietary target discovery platform PandaOmics. PandaClaw combines AI agents with biological and bioinformatics workflows, enabling researchers to perform automated real-time analysis through an intuitive, intelligent natural language interface. This facilitates efficient and convenient completion of complex biological tasks such as target discovery, indication exploration, and disease hypothesis generation, thereby accelerating translational medical research.

It is reported that PandaClaw marks another important milestone for Silicon Smart in advancing toward “pharmaceutical super-intelligence.” Within the PandaOmics ecosystem, this evolution began with the launch of ChatPandaGPT in March 2023, which allows users to interact with literature and knowledge graphs using natural language. In July 2024, Silicon Smart completed an iteration of this feature and internally released AskPanda, enabling users to directly query analysis results for specific targets (Target ID) within the platform. Based on previous practical experience, PandaClaw, as a complete biological analysis intelligent agent, was officially launched in March 2026.

(Edited by: Liu Jing HZ010)

【Disclaimer】This article only reflects the author’s personal views and is not related to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions expressed in this article and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use this information for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.